Global Crigler-Najjar Syndrome Drug Market Growth 2025-2031

January 2025 | 82 pages | ID: GE1226574F89EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Crigler-Najjar Syndrome Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the “Crigler-Najjar Syndrome Drug Industry Forecast” looks at past sales and reviews total world Crigler-Najjar Syndrome Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Crigler-Najjar Syndrome Drug sales for 2025 through 2031. With Crigler-Najjar Syndrome Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Crigler-Najjar Syndrome Drug industry.

This Insight Report provides a comprehensive analysis of the global Crigler-Najjar Syndrome Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Crigler-Najjar Syndrome Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Crigler-Najjar Syndrome Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Crigler-Najjar Syndrome Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Crigler-Najjar Syndrome Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Crigler-Najjar Syndrome Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• ALXN-1540
• AT-342
• HepaStem
• Others

Segmentation by Application:

• Hospital
• Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Audentes Therapeutics Inc
• Genethon SA
• International Stem Cell Corp
• Promethera Biosciences SA

Key Questions Addressed in this Report

What is the 10-year outlook for the global Crigler-Najjar Syndrome Drug market?

What factors are driving Crigler-Najjar Syndrome Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Crigler-Najjar Syndrome Drug market opportunities vary by end market size?

How does Crigler-Najjar Syndrome Drug break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Crigler-Najjar Syndrome Drug Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Crigler-Najjar Syndrome Drug by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Crigler-Najjar Syndrome Drug by Country/Region, 2020, 2024 & 2031
2.2 Crigler-Najjar Syndrome Drug Segment by Type
  2.2.1 ALXN-1540
  2.2.2 AT-342
  2.2.3 HepaStem
  2.2.4 Others
2.3 Crigler-Najjar Syndrome Drug Sales by Type
  2.3.1 Global Crigler-Najjar Syndrome Drug Sales Market Share by Type (2020-2025)
  2.3.2 Global Crigler-Najjar Syndrome Drug Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Crigler-Najjar Syndrome Drug Sale Price by Type (2020-2025)
2.4 Crigler-Najjar Syndrome Drug Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 Others
2.5 Crigler-Najjar Syndrome Drug Sales by Application
  2.5.1 Global Crigler-Najjar Syndrome Drug Sale Market Share by Application (2020-2025)
  2.5.2 Global Crigler-Najjar Syndrome Drug Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Crigler-Najjar Syndrome Drug Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Crigler-Najjar Syndrome Drug Breakdown Data by Company
  3.1.1 Global Crigler-Najjar Syndrome Drug Annual Sales by Company (2020-2025)
  3.1.2 Global Crigler-Najjar Syndrome Drug Sales Market Share by Company (2020-2025)
3.2 Global Crigler-Najjar Syndrome Drug Annual Revenue by Company (2020-2025)
  3.2.1 Global Crigler-Najjar Syndrome Drug Revenue by Company (2020-2025)
  3.2.2 Global Crigler-Najjar Syndrome Drug Revenue Market Share by Company (2020-2025)
3.3 Global Crigler-Najjar Syndrome Drug Sale Price by Company
3.4 Key Manufacturers Crigler-Najjar Syndrome Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Crigler-Najjar Syndrome Drug Product Location Distribution
  3.4.2 Players Crigler-Najjar Syndrome Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR CRIGLER-NAJJAR SYNDROME DRUG BY GEOGRAPHIC REGION

4.1 World Historic Crigler-Najjar Syndrome Drug Market Size by Geographic Region (2020-2025)
  4.1.1 Global Crigler-Najjar Syndrome Drug Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Crigler-Najjar Syndrome Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Crigler-Najjar Syndrome Drug Market Size by Country/Region (2020-2025)
  4.2.1 Global Crigler-Najjar Syndrome Drug Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Crigler-Najjar Syndrome Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Crigler-Najjar Syndrome Drug Sales Growth
4.4 APAC Crigler-Najjar Syndrome Drug Sales Growth
4.5 Europe Crigler-Najjar Syndrome Drug Sales Growth
4.6 Middle East & Africa Crigler-Najjar Syndrome Drug Sales Growth

5 AMERICAS

5.1 Americas Crigler-Najjar Syndrome Drug Sales by Country
  5.1.1 Americas Crigler-Najjar Syndrome Drug Sales by Country (2020-2025)
  5.1.2 Americas Crigler-Najjar Syndrome Drug Revenue by Country (2020-2025)
5.2 Americas Crigler-Najjar Syndrome Drug Sales by Type (2020-2025)
5.3 Americas Crigler-Najjar Syndrome Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Crigler-Najjar Syndrome Drug Sales by Region
  6.1.1 APAC Crigler-Najjar Syndrome Drug Sales by Region (2020-2025)
  6.1.2 APAC Crigler-Najjar Syndrome Drug Revenue by Region (2020-2025)
6.2 APAC Crigler-Najjar Syndrome Drug Sales by Type (2020-2025)
6.3 APAC Crigler-Najjar Syndrome Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Crigler-Najjar Syndrome Drug by Country
  7.1.1 Europe Crigler-Najjar Syndrome Drug Sales by Country (2020-2025)
  7.1.2 Europe Crigler-Najjar Syndrome Drug Revenue by Country (2020-2025)
7.2 Europe Crigler-Najjar Syndrome Drug Sales by Type (2020-2025)
7.3 Europe Crigler-Najjar Syndrome Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Crigler-Najjar Syndrome Drug by Country
  8.1.1 Middle East & Africa Crigler-Najjar Syndrome Drug Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Crigler-Najjar Syndrome Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Crigler-Najjar Syndrome Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Crigler-Najjar Syndrome Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Crigler-Najjar Syndrome Drug
10.3 Manufacturing Process Analysis of Crigler-Najjar Syndrome Drug
10.4 Industry Chain Structure of Crigler-Najjar Syndrome Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Crigler-Najjar Syndrome Drug Distributors
11.3 Crigler-Najjar Syndrome Drug Customer

12 WORLD FORECAST REVIEW FOR CRIGLER-NAJJAR SYNDROME DRUG BY GEOGRAPHIC REGION

12.1 Global Crigler-Najjar Syndrome Drug Market Size Forecast by Region
  12.1.1 Global Crigler-Najjar Syndrome Drug Forecast by Region (2026-2031)
  12.1.2 Global Crigler-Najjar Syndrome Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Crigler-Najjar Syndrome Drug Forecast by Type (2026-2031)
12.7 Global Crigler-Najjar Syndrome Drug Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Audentes Therapeutics Inc
  13.1.1 Audentes Therapeutics Inc Company Information
  13.1.2 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
  13.1.3 Audentes Therapeutics Inc Crigler-Najjar Syndrome Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Audentes Therapeutics Inc Main Business Overview
  13.1.5 Audentes Therapeutics Inc Latest Developments
13.2 Genethon SA
  13.2.1 Genethon SA Company Information
  13.2.2 Genethon SA Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
  13.2.3 Genethon SA Crigler-Najjar Syndrome Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Genethon SA Main Business Overview
  13.2.5 Genethon SA Latest Developments
13.3 International Stem Cell Corp
  13.3.1 International Stem Cell Corp Company Information
  13.3.2 International Stem Cell Corp Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
  13.3.3 International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 International Stem Cell Corp Main Business Overview
  13.3.5 International Stem Cell Corp Latest Developments
13.4 Promethera Biosciences SA
  13.4.1 Promethera Biosciences SA Company Information
  13.4.2 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
  13.4.3 Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Promethera Biosciences SA Main Business Overview
  13.4.5 Promethera Biosciences SA Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Crigler-Najjar Syndrome Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Crigler-Najjar Syndrome Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of ALXN-1540
Table 4. Major Players of AT-342
Table 5. Major Players of HepaStem
Table 6. Major Players of Others
Table 7. Global Crigler-Najjar Syndrome Drug Sales byType (2020-2025) & (K Pcs)
Table 8. Global Crigler-Najjar Syndrome Drug Sales Market Share byType (2020-2025)
Table 9. Global Crigler-Najjar Syndrome Drug Revenue byType (2020-2025) & ($ million)
Table 10. Global Crigler-Najjar Syndrome Drug Revenue Market Share byType (2020-2025)
Table 11. Global Crigler-Najjar Syndrome Drug Sale Price byType (2020-2025) & (USD/Pcs)
Table 12. Global Crigler-Najjar Syndrome Drug Sale by Application (2020-2025) & (K Pcs)
Table 13. Global Crigler-Najjar Syndrome Drug Sale Market Share by Application (2020-2025)
Table 14. Global Crigler-Najjar Syndrome Drug Revenue by Application (2020-2025) & ($ million)
Table 15. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Application (2020-2025)
Table 16. Global Crigler-Najjar Syndrome Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 17. Global Crigler-Najjar Syndrome Drug Sales by Company (2020-2025) & (K Pcs)
Table 18. Global Crigler-Najjar Syndrome Drug Sales Market Share by Company (2020-2025)
Table 19. Global Crigler-Najjar Syndrome Drug Revenue by Company (2020-2025) & ($ millions)
Table 20. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Company (2020-2025)
Table 21. Global Crigler-Najjar Syndrome Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 22. Key Manufacturers Crigler-Najjar Syndrome Drug Producing Area Distribution and Sales Area
Table 23. Players Crigler-Najjar Syndrome Drug Products Offered
Table 24. Crigler-Najjar Syndrome Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Crigler-Najjar Syndrome Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 28. Global Crigler-Najjar Syndrome Drug Sales Market Share Geographic Region (2020-2025)
Table 29. Global Crigler-Najjar Syndrome Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 30. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Geographic Region (2020-2025)
Table 31. Global Crigler-Najjar Syndrome Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 32. Global Crigler-Najjar Syndrome Drug Sales Market Share by Country/Region (2020-2025)
Table 33. Global Crigler-Najjar Syndrome Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 34. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Country/Region (2020-2025)
Table 35. Americas Crigler-Najjar Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
Table 36. Americas Crigler-Najjar Syndrome Drug Sales Market Share by Country (2020-2025)
Table 37. Americas Crigler-Najjar Syndrome Drug Revenue by Country (2020-2025) & ($ millions)
Table 38. Americas Crigler-Najjar Syndrome Drug Sales byType (2020-2025) & (K Pcs)
Table 39. Americas Crigler-Najjar Syndrome Drug Sales by Application (2020-2025) & (K Pcs)
Table 40. APAC Crigler-Najjar Syndrome Drug Sales by Region (2020-2025) & (K Pcs)
Table 41. APAC Crigler-Najjar Syndrome Drug Sales Market Share by Region (2020-2025)
Table 42. APAC Crigler-Najjar Syndrome Drug Revenue by Region (2020-2025) & ($ millions)
Table 43. APAC Crigler-Najjar Syndrome Drug Sales byType (2020-2025) & (K Pcs)
Table 44. APAC Crigler-Najjar Syndrome Drug Sales by Application (2020-2025) & (K Pcs)
Table 45. Europe Crigler-Najjar Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
Table 46. Europe Crigler-Najjar Syndrome Drug Revenue by Country (2020-2025) & ($ millions)
Table 47. Europe Crigler-Najjar Syndrome Drug Sales byType (2020-2025) & (K Pcs)
Table 48. Europe Crigler-Najjar Syndrome Drug Sales by Application (2020-2025) & (K Pcs)
Table 49. Middle East & Africa Crigler-Najjar Syndrome Drug Sales by Country (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Crigler-Najjar Syndrome Drug Revenue Market Share by Country (2020-2025)
Table 51. Middle East & Africa Crigler-Najjar Syndrome Drug Sales byType (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Crigler-Najjar Syndrome Drug Sales by Application (2020-2025) & (K Pcs)
Table 53. Key Market Drivers & Growth Opportunities of Crigler-Najjar Syndrome Drug
Table 54. Key Market Challenges & Risks of Crigler-Najjar Syndrome Drug
Table 55. Key IndustryTrends of Crigler-Najjar Syndrome Drug
Table 56. Crigler-Najjar Syndrome Drug Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Crigler-Najjar Syndrome Drug Distributors List
Table 59. Crigler-Najjar Syndrome Drug Customer List
Table 60. Global Crigler-Najjar Syndrome Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 61. Global Crigler-Najjar Syndrome Drug RevenueForecast by Region (2026-2031) & ($ millions)
Table 62. Americas Crigler-Najjar Syndrome Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 63. Americas Crigler-Najjar Syndrome Drug Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 64. APAC Crigler-Najjar Syndrome Drug SalesForecast by Region (2026-2031) & (K Pcs)
Table 65. APAC Crigler-Najjar Syndrome Drug Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 66. Europe Crigler-Najjar Syndrome Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 67. Europe Crigler-Najjar Syndrome Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 68. Middle East & Africa Crigler-Najjar Syndrome Drug SalesForecast by Country (2026-2031) & (K Pcs)
Table 69. Middle East & Africa Crigler-Najjar Syndrome Drug RevenueForecast by Country (2026-2031) & ($ millions)
Table 70. Global Crigler-Najjar Syndrome Drug SalesForecast byType (2026-2031) & (K Pcs)
Table 71. Global Crigler-Najjar Syndrome Drug RevenueForecast byType (2026-2031) & ($ millions)
Table 72. Global Crigler-Najjar Syndrome Drug SalesForecast by Application (2026-2031) & (K Pcs)
Table 73. Global Crigler-Najjar Syndrome Drug RevenueForecast by Application (2026-2031) & ($ millions)
Table 74. AudentesTherapeutics Inc Basic Information, Crigler-Najjar Syndrome Drug Manufacturing Base, Sales Area and Its Competitors
Table 75. AudentesTherapeutics Inc Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
Table 76. AudentesTherapeutics Inc Crigler-Najjar Syndrome Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 77. AudentesTherapeutics Inc Main Business
Table 78. AudentesTherapeutics Inc Latest Developments
Table 79. Genethon SA Basic Information, Crigler-Najjar Syndrome Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Genethon SA Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
Table 81. Genethon SA Crigler-Najjar Syndrome Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 82. Genethon SA Main Business
Table 83. Genethon SA Latest Developments
Table 84. International Stem Cell Corp Basic Information, Crigler-Najjar Syndrome Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. International Stem Cell Corp Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
Table 86. International Stem Cell Corp Crigler-Najjar Syndrome Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 87. International Stem Cell Corp Main Business
Table 88. International Stem Cell Corp Latest Developments
Table 89. Promethera Biosciences SA Basic Information, Crigler-Najjar Syndrome Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Product Portfolios and Specifications
Table 91. Promethera Biosciences SA Crigler-Najjar Syndrome Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 92. Promethera Biosciences SA Main Business
Table 93. Promethera Biosciences SA Latest Developments



LIST OFFIGURES

Figure 1. Picture of Crigler-Najjar Syndrome Drug
Figure 2. Crigler-Najjar Syndrome Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Crigler-Najjar Syndrome Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Crigler-Najjar Syndrome Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Crigler-Najjar Syndrome Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Crigler-Najjar Syndrome Drug Sales Market Share by Country/Region (2024)
Figure 10. Crigler-Najjar Syndrome Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of ALXN-1540
Figure 12. Product Picture of AT-342
Figure 13. Product Picture of HepaStem
Figure 14. Product Picture of Others
Figure 15. Global Crigler-Najjar Syndrome Drug Sales Market Share byType in 2025
Figure 16. Global Crigler-Najjar Syndrome Drug Revenue Market Share byType (2020-2025)
Figure 17. Crigler-Najjar Syndrome Drug Consumed in Hospital
Figure 18. Global Crigler-Najjar Syndrome Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 19. Crigler-Najjar Syndrome Drug Consumed in Clinic
Figure 20. Global Crigler-Najjar Syndrome Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 21. Crigler-Najjar Syndrome Drug Consumed in Others
Figure 22. Global Crigler-Najjar Syndrome Drug Market: Others (2020-2025) & (K Pcs)
Figure 23. Global Crigler-Najjar Syndrome Drug Sale Market Share by Application (2024)
Figure 24. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Application in 2025
Figure 25. Crigler-Najjar Syndrome Drug Sales by Company in 2025 (K Pcs)
Figure 26. Global Crigler-Najjar Syndrome Drug Sales Market Share by Company in 2025
Figure 27. Crigler-Najjar Syndrome Drug Revenue by Company in 2025 ($ millions)
Figure 28. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Company in 2025
Figure 29. Global Crigler-Najjar Syndrome Drug Sales Market Share by Geographic Region (2020-2025)
Figure 30. Global Crigler-Najjar Syndrome Drug Revenue Market Share by Geographic Region in 2025
Figure 31. Americas Crigler-Najjar Syndrome Drug Sales 2020-2025 (K Pcs)
Figure 32. Americas Crigler-Najjar Syndrome Drug Revenue 2020-2025 ($ millions)
Figure 33. APAC Crigler-Najjar Syndrome Drug Sales 2020-2025 (K Pcs)
Figure 34. APAC Crigler-Najjar Syndrome Drug Revenue 2020-2025 ($ millions)
Figure 35. Europe Crigler-Najjar Syndrome Drug Sales 2020-2025 (K Pcs)
Figure 36. Europe Crigler-Najjar Syndrome Drug Revenue 2020-2025 ($ millions)
Figure 37. Middle East & Africa Crigler-Najjar Syndrome Drug Sales 2020-2025 (K Pcs)
Figure 38. Middle East & Africa Crigler-Najjar Syndrome Drug Revenue 2020-2025 ($ millions)
Figure 39. Americas Crigler-Najjar Syndrome Drug Sales Market Share by Country in 2025
Figure 40. Americas Crigler-Najjar Syndrome Drug Revenue Market Share by Country (2020-2025)
Figure 41. Americas Crigler-Najjar Syndrome Drug Sales Market Share byType (2020-2025)
Figure 42. Americas Crigler-Najjar Syndrome Drug Sales Market Share by Application (2020-2025)
Figure 43. United States Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Canada Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Mexico Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Brazil Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. APAC Crigler-Najjar Syndrome Drug Sales Market Share by Region in 2025
Figure 48. APAC Crigler-Najjar Syndrome Drug Revenue Market Share by Region (2020-2025)
Figure 49. APAC Crigler-Najjar Syndrome Drug Sales Market Share byType (2020-2025)
Figure 50. APAC Crigler-Najjar Syndrome Drug Sales Market Share by Application (2020-2025)
Figure 51. China Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Japan Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. South Korea Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Southeast Asia Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. India Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Australia Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. ChinaTaiwan Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Europe Crigler-Najjar Syndrome Drug Sales Market Share by Country in 2025
Figure 59. Europe Crigler-Najjar Syndrome Drug Revenue Market Share by Country (2020-2025)
Figure 60. Europe Crigler-Najjar Syndrome Drug Sales Market Share byType (2020-2025)
Figure 61. Europe Crigler-Najjar Syndrome Drug Sales Market Share by Application (2020-2025)
Figure 62. Germany Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 63.France Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. UK Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Italy Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Russia Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Middle East & Africa Crigler-Najjar Syndrome Drug Sales Market Share by Country (2020-2025)
Figure 68. Middle East & Africa Crigler-Najjar Syndrome Drug Sales Market Share byType (2020-2025)
Figure 69. Middle East & Africa Crigler-Najjar Syndrome Drug Sales Market Share by Application (2020-2025)
Figure 70. Egypt Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. South Africa Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. Israel Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 73.Turkey Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. GCC Countries Crigler-Najjar Syndrome Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Crigler-Najjar Syndrome Drug in 2025
Figure 76. Manufacturing Process Analysis of Crigler-Najjar Syndrome Drug
Figure 77. Industry Chain Structure of Crigler-Najjar Syndrome Drug
Figure 78. Channels of Distribution
Figure 79. Global Crigler-Najjar Syndrome Drug Sales MarketForecast by Region (2026-2031)
Figure 80. Global Crigler-Najjar Syndrome Drug Revenue Market ShareForecast by Region (2026-2031)
Figure 81. Global Crigler-Najjar Syndrome Drug Sales Market ShareForecast byType (2026-2031)
Figure 82. Global Crigler-Najjar Syndrome Drug Revenue Market ShareForecast byType (2026-2031)
Figure 83. Global Crigler-Najjar Syndrome Drug Sales Market ShareForecast by Application (2026-2031)
Figure 84. Global Crigler-Najjar Syndrome Drug Revenue Market ShareForecast by Application (2026-2031)